A Rabbit Polyclonal Antibodies Specific for S113 and S117 Phosphorylated Sam68 (Src-associated substrate in mitosis of 68 kDa), an RNA-binding Protein with Multi-functions in the Cell

Value Proposition

• Binds a potential novel target for pharmacological interventions, as monoclonal antibodies against CD25 are a significant treatment for C25 expressed cancers.
• Reports phosphorylation of S113 and S117 residues in Sam68, which is critical for the NF-kB-mediated selective transcription of the CD25 gene.

Unmet Need

• Annually, there are approximately 20 million cancer cases and 9.7 million cancer related deaths worldwide (NIH). The complex nature of the illness makes diagnosis and treatment highly case-specific, requiring a multitude of methods. CD25 expression, resulting in aberrant signaling in the tumors, can lead to increased proliferation, anti-apoptotic protein expression and drug resistance. Thus, there exists a strong need to develop therapies against CD25.   

Technology Description

• CD25, the alpha chain of the interleukin-2 receptor, is expressed in T-cells during autoimmune disease and tumorigenesis. Researchers at Johns Hopkins have elucidated CD25’s transcriptional mechanism and developed an antibody to target the pathway necessary for its transcription.

Stage of Development

• The antibody has been purified and has demonstrated activity in vitro.

Data Availability

• Data available upon request.

Publication

N/A